Drug Database
GL

glimepiride + metformin SR (Amaryl Mex / Amaryl M SR)

✓ Approved

Sanofi S.A · KCNJ11 · 小分子

什么是 glimepiride + metformin SR?

glimepiride + metformin SR 是一种小分子,由Sanofi S.A研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Amaryl Mex, Amaryl M SR
公司Sanofi S.A
药物类别小分子
分子靶点KCNJ11, ABCC8
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

glimepiride + metformin SR 作用于 2 个分子靶点:

KCNJ11potassium inwardly rectifying channel subfamily J member 11 (BIR, HHF2)
ABCC8ATP binding cassette subfamily C member 8 (MRP8, SUR1delta2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

glimepiride + metformin SR 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

相关研究文献

PubMedCommunications chemistry2026-11-19

Critical size for metallization in core-derived epitaxial growth of thiolate-protected gold nanoclusters studied through Au171(SR)65 and Au207(SR)80 assembly.

Mo Minjun M, Ning Ting T, Pei Yong Y, Xiong Lin L

The structural design and metallization mechanism of large gold nanoclusters remain fundamental challenges in nanocluster science. Here we show a "core-derived epitaxial growth" strategy, in which intercross-sharing Au19 and vertex-sharing Au25 cores serve as initial templates to construct two larger clusters, Au171(SR)65 and Au207(SR)80. Density functional theory calculations confirm their high structural stability. Electronic structure analysis reveals discrete energy levels between -12 eV and 2 eV, dominated by gold atomic orbitals, indicating retained molecular-state character. Although both clusters exhibit narrow bandgaps, Au171(SR)65 lacks a surface plasmon resonance peak and shows weaker electron delocalization, confirming its molecular nature. Au207(SR)80, by contrast, displays a weak plasmon-like peak at 531 nm, suggesting only incipient metallic behavior. This work presents a new route for constructing large gold clusters and underscores the decisive role of core assembly patterns in governing the critical transition to metallicity, providing valuable insights into quantum confinement and metallic evolution in gold nanoclusters.

PMID 43052379
阅读全文 →
PubMedBMC urology2026-11-18

Association of metformin use with metabolic trajectories and disease progression in prostate cancer patients receiving androgen deprivation therapy: a target trial emulation study.

He Yongkai Y, Tang Liang L, Yuan Kun K, Liu HuiYing H et al.

Androgen deprivation therapy (ADT) is associated with substantial metabolic deterioration in patients with prostate cancer. Metformin may attenuate ADT-related metabolic complications, although its association with longitudinal metabolic trajectories and prostate cancer outcomes remains uncertain. We conducted a retrospective cohort study emulating a target trial using a 90-day landmark design. Patients with prostate adenocarcinoma initiating ADT between 2015 and 2020 were classified according to metformin exposure during the landmark window (T₀ = Day 90 after ADT initiation). Metformin users initiated and maintained metformin treatment for at least 90 days, whereas controls had no metformin exposure. IPTW was applied to balance baseline characteristics. Longitudinal metabolic outcomes were assessed using weighted linear mixed-effects models, and progression outcomes were analyzed using weighted Cox models. Among 823 screened patients, 342 were included in the final analysis (171 metformin users and 171 controls). After IPTW adjustment, baseline covariates were well balanced. Compared with controls, metformin exposure was associated with smaller increases in HbA1c (adjusted difference - 0.34%, 95% CI - 0.58 to - 0.10) and triglycerides (- 26 mg/dL, 95% CI - 46 to - 6) during follow-up. Metformin exposure was also associated with lower observed risks of PSA progression (HR 0.71, 95% CI 0.52-0.96) and CRPC progression (HR 0.67, 95% CI 0.47-0.95), although these findings were considered exploratory because of limited event numbers. Metformin exposure was associated with less ADT-related metabolic deterioration and lower observed progression rates. These findings do not establish an anticancer effect and require confirmation in randomized studies.

PMID 43046007
阅读全文 →
PubMedBehavioural brain research2026-11-18

Metformin Preserves Hippocampal and Prefrontal Synaptic Integrity in Rats with Spinal Cord Injury: SIRT1 Induction and microRNA Modulation.

Kandemir Turan T, Ergen Fulya Büge FB, Coşan Didem Turgut DT, Özkara Emre E et al.

Spinal cord injury (SCI) is associated with memory-related behavioral deficits and dendritic alterations in supraspinal brain regions. We investigated whether metformin improves recognition-related behavior after SCI and examined accompanying structural and molecular changes. Adult female rats underwent clip-compression SCI and received daily intraperitoneal saline or metformin (50mg/kg) for 7 or 14 days; unoperated rats served as controls. Behavioral assessments included novel object recognition (NOR), Basso-Beattie-Bresnahan (BBB) locomotor scoring, and elevated plus maze (EPM) closed-arm-entry latency as an activity-related measure. Nissl and Golgi-Cox staining evaluated neuronal density and dendritic morphology in the hippocampus and prefrontal cortex. Hippocampal gene expression and protein concentrations were assessed using quantitative PCR and ELISA. NOR acquisition indices were similar across groups, whereas NOR discrimination was lower in saline-treated SCI rats than in controls at both time points. Metformin increased NOR discrimination versus saline at 14 days (p < 0.0001), but not at 7 days, and improved BBB recovery in both cohorts (p < 0.0001). EPM closed-arm-entry latency was shorter with metformin at both time points (p < 0.001). At 14 days, metformin-treated rats showed higher dendritic spine density in the prefrontal cortex and hippocampal CA1 (both p < 0.0001), higher hippocampal sirtuin 1 and brain-derived neurotrophic factor protein concentrations, and lower miR-132, miR-134, miR-138, and Rock1 expression than saline-treated SCI rats. Metformin was associated with improved recognition-related behavioral performance and locomotor recovery following SCI, accompanied by preservation of dendritic spine density and alterations in hippocampal plasticity-related markers.

PMID 43051322
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Comparison of the Efficacy of Kligman's Formula Combined With 30% Topical Metformin Versus Kligman's Formula Alone in the Treatment of Melasma.

Iraji Fariba F, Mokhtari Fatemeh F, Kassab Zeinab Z, Seyedyousefi Sarah S et al.

Melasma is a common hyperpigmentation disorder primarily affecting women, influenced by ultraviolet exposure, hormones, and genetics. Kligman's formula is a first-line therapy, but emerging evidence suggests that topical metformin, an antidiabetic with antimelanogenic effects, may enhance treatment outcomes. The objective of this study is to compare the efficacy and safety of Kligman's formula with and without 30% topical metformin in bilateral facial melasma. In this randomized, double-blind, split-face clinical trial, 31 patients with symmetrical facial melasma applied Cream A (Kligman's formula + 30% metformin) to one side and Cream B (Kligman's formula alone) to the other for 2 months. Outcomes included MASI scores, repigmentation grading, patient satisfaction via Visual Analog Scale (VAS), and side effect profiles assessed at baseline, post-treatment, and 2 months after discontinuation. Both treatments significantly reduced pigmentation and improved homogeneity. Cream B showed a slightly greater reduction in darkness, while Cream A led to more stable repigmentation and fewer cases of post-inflammatory hyperpigmentation. No significant differences were found between post-treatment and follow-up scores. VAS scores indicated high patient satisfaction across both groups. Adding 30% topical metformin to Kligman's formula is safe and comparably effective in melasma treatment, offering potential benefits in pigment stability and reduced PIH. Although differences were not statistically significant, clinical trends support further investigation through larger, long-term studies. ClinicalTrials.gov identifier: IRCT20150706023081N2.

PMID 43047029
阅读全文 →
PubMedMayo Clinic proceedings2026-11-18

SGLT2 Inhibitors Versus Metformin as First-Line Therapy for Cardiorenal Outcomes: A Target Trial Emulation Among New Users With Type 2 Diabetes.

Kung Fang-Ping FP, Tsai Ching-Fang CF, Chang Yu-Tzu YT

To compare cardiorenal and mortality outcomes associated with initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors versus metformin as first-line glucose-lowering therapy among new users with type 2 diabetes. Using a target trial emulation design with TriNetX Global Collaborative Network data, we identified adults (≥18 years) with type 2 diabetes who were new users of SGLT2 inhibitors or metformin from January 1, 2018, through December 31, 2023, with follow-up through June 10, 2025. The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes included individual MACE components, major adverse kidney events (MAKE), acute heart failure, all-cause mortality, and kidney failure requiring kidney replacement therapy. Propensity-score matching yielded 36,720 pairs. Over median follow-up of 2.5 and 3.5 years in the SGLT2 inhibitor and metformin groups, respectively, SGLT2 inhibitor initiation was associated with lower risks of MACE (HR, 0.88; 95% CI, 0.84-0.92), all-cause mortality (HR, 0.73; 95% CI, 0.68-0.77), stroke (HR, 0.84; 95% CI, 0.79-0.90), cardiac arrest (HR, 0.81; 95% CI, 0.68-0.95), and acute heart failure (HR, 0.94; 95% CI, 0.92-0.97). Myocardial infarction risk was similar between groups (HR, 0.97; 95% CI, 0.91-1.04). Kidney failure requiring kidney replacement therapy also did not differ significantly between groups (HR, 1.00; 95% CI, 0.87-1.14). Among new users with type 2 diabetes, first-line SGLT2 inhibitor initiation was associated with lower risks of MACE and all-cause mortality than metformin, while the risk of kidney failure requiring kidney replacement therapy was similar between groups.

PMID 43051408
阅读全文 →
PubMedClinical & experimental optometry2026-11-18

Comparison of refractive error measurements obtained with a pyramid wavefront sensor topo-aberrometer and an auto kerato-refractometer against subjective refraction.

Julien Alex A, Julio Gemma G, Junaidha Fathima F, Barraquer Rafael I RI

Refraction is a crucial part of an ocular examination. Ensuring the accuracy and efficiency of objective baseline measurements is essential for optimising clinical workflow and improving final prescription outcomes. Agreement between objective refraction of Topcon KR-800 auto kerato-refractometer and CSO Osiris-T topo-aberrometer with subjective refraction (SR), has never been evaluated before. This study aimed to evaluate the agreement and clinical interchangeability of these devices with SR. This observational cross-sectional study included patients with best corrected distance visual acuity ≥6/7.5. The proportions of spherical equivalent (SE) differences within ±0.25 D and ±0.50 D were reported descriptively. SE, cylinder, axis, J0 and J45 were compared, using Bland-Altman plots with 95% limits of agreement, and double-angle astigmatic plots of vectorial cylinder difference. The sample included 118 eyes of 60 women and 58 men with a mean (SD) age of 35.6 years (11.4), range 18 to 64 years. The percentages of differences between KR-800 and Osiris-T with SR were, respectively, 68.97% and 29.31% within ±0.25 D, and 92.24% and 59.48% within ±0.50 D. The mean spherical equivalent difference with SR was -0.09 D for KR-800 and 0.33 D for Osiris-T, and the 95% limits of agreement were -0.68 to 0.51 D and -0.54 to 1.21 D, respectively. The centroid of the vectorial astigmatic differences with SR was 0.04 D at 72º for KR-800 and 0.24 D at 41º for Osiris-T. Mean axis difference with SR was 2.47º (95% limits of agreement = -10.28 to 15.23º) for KR-800, and -2.73º (95% limits of agreement = -33.22 to 27.76º) for Osiris-T. Both devices provide a useful reference, but they are not interchangeable with SR. KR-800 demonstrated closer agreement with SR across all parameters.

PMID 43051136
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多glimepiride + metformin SR